Key Points Axsome Therapeutics has launched exciting new drugs over the past year, and they are delivering growth. The biopharma player’s late-stage pipeline could translate into additional products over the next few years. 10 stocks we like better than Axsome Therapeutics › Axsome Therapeutics (NASDAQ:AXSM) has seen its stock price climb over the past few years -- and for good reason. The company has progressively launched new products, confirming its expertise in the neuroscience space. This biotech aims to treat a variety of conditions linked to central nervous system (CNS) operations, from depression to migraine and narcolepsy.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.